“Modeling of Peripheral Neuropathic Pain and Osteoarthritis Placebo Response” presented at the International Society for CNS Clinical Trials and Methodology

February 21, 2020

Dr. Dominique Demolle, CEO of Tools4Patient, recently presented data at the 16th Annual Scientific Meeting of the International Society for CNS Clinical Trials and Methodology in Washington, DC. The presentation, entitled ““Modeling of Peripheral Neuropathic Pain and Osteoarthritis Placebo Response: Working Towards a Unique Model of the Placebo Response in Chronic Pain?” was authored by Tools4Patient scientist Dr. Samuel

Read More

Tools4Patient Selected as Finalist in 2019 Clinical Trials Innovations Challenge

September 16, 2019

Tools4Patient’s Placebell©™ technology has been selected as a finalist in the 2019 Clinical Trials Innovation Challenge sponsored by IQVIA, Lundbeck, and LEO Innovation Lab.

Read More

“Sensory Profiles and stratification of neuropathic pain patients based on the neuropathic pain symptom inventory (NPSI)” presented at the 2019 European Pain Federation EFIC Conference.

September 9, 2019

This study aimed to identify specific sensory phenotypes of peripheral neuropathic pain patients that could predict treatment response based on pain symptoms assessed by the Neuropathic Pain Symptom Inventory (NPSI).

Read More

Tools4Patient Raises Series B Financing for Commercial Expansion of Clinical Development Solutions

May 16, 2019

Placebell©™ technology designed to limit the negative impact of the placebo effect in clinical trials.

Read More

Opportunities Available for Collaboration

September 18, 2018

While drug developers have been struggling with the placebo response for decades, Placebell©™ is the first commercially available technology that enables scientists to control for the placebo response in clinical studies. Tools4Patient (T4P) launched Placebell©™ in late 2017,

Read More

Tools4Patient Strengthens Group’s Expertise with North American Business Development Team

May 22, 2018

The commercial launch of Placebell©™ for peripheral neuropathic pain in October 2017 has increased interest from biopharma industry stakeholders in T4P’s low-risk validated technology.

Read More

T4P Announces Initial Study to Validate Placebell©™ in Parkinson’s Disease

March 8, 2018

Following the commercial launch of Placebell©™ in peripheral neuropathic pain in October 2017 and the initiation of the validation of Placebell©™ in osteoarthritis in August 2017,

Read More